Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease
CompletedNCT02899871
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
IBD (inflammatory bowel disease) are associated with various types of joint manifestations, especially inflammatory. Patients with IBD treated with anti-TNF commonly report joint symptoms, with variable expressions and aetiologies, possibly responsible for impaired quality of life, and possibly leading to discontinuation of an effective and validated treatment.
Study details
- Official title
- Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease
- Conditions
- Interventions
- Other: diagnosis of joint
- Sponsor
- Centre Hospitalier Universitaire, Amiens
- Start date
- 2014-09
- Primary completion
- 2016-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Males or females over the age of 18 years at the time of inclusion * Patients with IBD (Crohn's disease or ulcerative colitis), diagnosed by a set of compatible clinical (chronic diarrhoea, haematochezia, anoperineal lesions, etc.), laboratory, histological and endoscopic arguments. Patients will be included regardless of the severity of their disease, its clinical course, the type of lesions, and the presence or absence of associated manifestations. * Patients treated with anti-TNF: infliximab or adalimumab. * Informed patients not refusing to participate. * Patients covered by French national health insurance. Exclusion Criteria: * Patients under the age of 18 years at the time of inclusion. * Patients previously treated with anti-TNF, but no longer treated with anti-TNF at the time of inclusion. * Protected majors (under permanent or temporary guardianship).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02899871